Chordomas are rare malignant tumors that are postulated to arise from remnants of the notochord. Currently, the interaction between chordomas and the host immune system is poorly understood. The checkpoint protein, PD-1 is expressed by circulating lymphocytes and is a marker of activation and exhaustion.
tumors typically arise from the axial skeleton and account for 1-4 % of all primary bone tumors and 0.1-0.2 % of all intracranial neoplasms [1, 2] . Surgical resection and radiation are the mainstays of treatment as no chemotherapeutics have been approved for chordomas [3, 4] . These tumors are associated with significant morbidity and mortality with survival rates at 5, 10, and 20 years of 67, 40 and 13 %, respectively [5] .
Despite extensive genetic and molecular analysis of cellular pathways implicated in chordoma pathogenesis, little is known about the interaction between chordomas and the host immune system [6] [7] [8] [9] [10] . Immune checkpoint proteins and their ligands are a group of surface-bound and secreted proteins that function to regulate immune responses to host proteins. This interaction serves as a potent negative signal for immune cells, rendering them exhausted or inactive (Fig. 1a) [11] .
Programmed death 1 (PD-1) and its ligands, PD-L1 (B7-H1, CD274) and PD-L2 (B7-DC, CD273), have been implicated in promoting progression of central nervous system tumors such as glioblastoma as well as solid tumors outside the central nervous system, including lung, gastric, and pancreatic cancers, among others [12] [13] [14] [15] [16] [17] . PD-1 is expressed on the surface of lymphocytes, and its ligands, PD-L1 and PD-L2, are expressed by tumor cells, tumorassociated immune cells, and stromal cells [14, 15] .
To date, no study has analyzed the PD-1 pathway in human chordomas. We used established chordoma cell lines and resected chordoma tissues to evaluate the expression of these surface markers in chordoma. We also assessed the inducible expression of PD-L1 and PD-L2 in chordoma cell lines, since cytokine stimulation has been associated with upregulated expression of these proteins in other tumors [25] .
Materials and methods
Three human chordoma cell lines and archived tissue from 10 patients were used to assess the levels of PD-1, PD-L1 and PD-L2 expression in chordomas.
Cell lines
The established human chordoma cell lines U-CH1 and U-CH2 were kindly provided by Dr. Michael Kelly (Duke University School of Medicine). U-CH1 is a chordoma cell line derived from a recurrent sacrococcygeal chordoma treated with radiation and UCH-2 is derived by a recurrent sacral tumor treated with radiation. JHC7, a third human chordoma cell line, is derived by a surgically resected primary spinal chordoma and was established as previously described [18] . The U-CH1 and U-CH2 cell lines were cultured in gelatin coated flasks and were grown with IMDM-RPMI media (4:1) supplemented with 10 % FBS and 1 % penicillin-streptomycin. The JHC7 cell line was cultured in non-gelatin coated flasks. Cells were grown in MesenPRO basal media plus supplement (Invitrogen, Carlsbad, California, USA), 5 mM glutamine, and 1 % antibiotic and antimycotic for the first 2 passages and were switched to DMEM supplemented with 10 % FBS and 1 % penicillin-streptomycin in sequential passages. All three cell lines were incubated at 37°C in a humidified atmosphere containing 5 % CO 2 .
Flow cytometry
Surface expression of PD-L1 and PD-L2 was assessed in the U-CH1, U-CH2, and JHC7 cell lines. Baseline expression and inducible PD-L1 and PD-L2 expression were assessed after interferon-gamma (IFN-c) and interleukin-4 (IL-4) treatments. Cells were treated with IFN-c at a dose of 10 ng/ml (eBioscience, San Diego, California, USA) or IL-4 (eBioscience) at a dose of 50 ng/ml for 24 h. Cells were trypsinized, washed with PBS, and stained with PD-L1 PE Cy7 (eBioscience) and PD-L2 APC or PE (eBioscience). Aqua fixable viability dye (Life Technologies, Grand Island, New York, USA) was used to exclude dead cells from the analysis. Stained cells were analyzed using a LSR II flow cytometer (BD Biosciences, San Jose, California, USA). Data analysis was performed with FlowJo software (Tree Star Inc., Ashland, Oregon, USA). We considered positive PDL1, PDL2 staining only when and IL-4 (50 ng/ml). Tumor RNA was extracted using the RNeasy Mini Kit (Qiagen, Valencia, California, USA) according to the manufacturer's protocol. 1 lg of RNA was used for cDNA synthesis using the QuantiTect Reverse Transcription Kit (Qiagen) in order to synthesize 100 ll of cDNA. RT-PCR was performed using the Step-One Plus detection system (Applied Biosystems, Grand Island, New York, USA). Reactions were performed at a final volume of 25 ll which contained 1 ll cDNA, 12.5 ll TaqMan Universal Master Mix (Applied Biosystems), 1.25 ll of 18s VIC-TAMRA rRNA primer mix (Applied Biosystems), 1.25 ll of primer mix (sense and anti-sense) of the gene of interest and 9 ll of DEPC treated water. All oligonucleotide primers for RT-PCR were synthesized by Applied Biosystems (Table S1 ). The same thermal profile conditions were used for all primer sets. Samples were run in triplicate. The 2-DDCt was used to analyze the relative gene expression of the stimulated groups versus controls. All RT-PCR experiments have been repeated three times (three independent experiments) with similar results. One RT-PCR round of the three has been used to draw statistical conclusions.
Immunohistochemistry (IHC) for PD-1 and PD-L1
IHC was performed on 10 formalin-fixed, paraffin embedded (FFPE) blocks from chordoma samples identified in the Johns Hopkins Hospital surgical pathology archives. Samples were cut in 5 lm-thick sections and stained for PD-1 or PD-L1 as previously described [19, 20] . 1.8 lg/ll of 5H1 monoclonal antibody (mAb) was used for PD-L1 staining, and 1 lg/ll of M3 mAb was used for PD-1 staining. Tonsil tissue was used as both a positive and negative control for PD-1 staining. An IgG isotype control was used for PD-L1 staining. In addition, native tissue elements also served as internal positive and negative controls for both PD-1 and PD-L1 staining. Tumor cells and infiltrating immune cells were scored separately for PD-L1 expression, with a threshold of [5 % membranous expression considered to be positive. 20 A threshold [5 % of tumor infiltrating lymphocytes (TIL) expressing PD-1 was also used to consider a case positive for PD-1. CD3 and CD68 IHC for all cases was performed according to standard automated protocol. Three board-certified pathologists (JMT, PCB, EFM) independently scored PD-1 and PD-L1 staining and the geographic co-localization of these markers within the tumor microenvironment.
Patient data
Patient information, including tumor location, previous treatment, surgical margins, and tumor recurrence were obtained by retrospective review of 10 patients treated at the Johns Hopkins Hospital. Collection of all patient information was completed with institutional review board approval from the Johns Hopkins institutional review board committee.
Statistical analysis
Statistical analysis was performed using Prism 6 (GraphPad Software Inc., San Diego, California, USA). Differences between groups were assessed using an unpaired, 
-DDCt method were calculated using Data Assist (Applied Biosystems).
Results

Inducible membranous expression of PD-L1 and PD-L2 proteins is present in chordoma cell lines
Membranous expression of PD-L1 and PD-L2 on patient derived chordoma cell lines was confirmed by flow cytometry in the U-CH1, U-CH2, and JHC7 cell lines. All cell lines expressed basal levels of PD-L1 (Fig. 1a) and PD-L2 (Fig. 1b) Table 1 . Collectively, these findings suggest that a subset of chordomas express the PD-1/PD-L1 pathway. 
Discussion
The discovery of key genes, such as brachyury, and oncogenic signaling pathways, such as the Akt/PI3 kinase pathway, has improved our understanding of chordoma pathogenesis [6, 21] . The interaction between chordomas and the host immune system, however, remains poorly understood. Many cancers have evolved mechanisms to suppress and evade the host immune system and significant progress has been made in understanding and reversing tumor-mediated immune tolerance [22] . PD-1/PD-L1 blockade is a promising approach that is being actively investigated for clinical translation in a variety of cancers [23] . Whether this pathway plays a role in chordoma pathogenesis and progression, to our knowledge, has not been previously investigated.
The lack of an immunocompetent mouse chordoma model makes the study of any immunological aspect of this tumor type difficult. Patient derived xenografts as well as human chordoma cell lines can grow in immunodeficient mice including NOD/SCID IL2rg (-/-) that lack B, T and natural killer (NK) activity and Nude mice lacking B, T cell function but maintaining intact NK cells. One approach to study chordoma immunology in mice is through the creation of a ''humanized'' mouse model. In this model, mice are depleted of their mouse bone marrow and human CD34? hematopoietic stem cells are engrafted in the bone marrow instead, before human chordoma cells are implanted in the mice. This method is complex because of cost, time, issues with histocompatibility antigens, and heterogeneity in the achieved levels of the mouse ''humanization'' [24] .
In this manuscript we study the expression of the PD-1 pathway in human chordomas, a first step that sets the basis for future studies to perform a more in depth analysis of this pathway and its involvement in chordomas. In our cohort, 67 and 50 % of patient samples that contained tumor infiltrating immune cells showed positive staining for PD-L1 and PD-1, respectively. Interestingly, expression of PD-L1 localized to tumor infiltrating immune cells rather than chordoma tumor cells despite chordoma cell lines clearly demonstrating the ability to up-regulate PD-L1 expression in the setting of pro-inflammatory cytokines. These data suggest that chordomas may not be subject to significant baseline immunologic pressure, but have the capacity to implement immunologic escape mechanisms in the setting of an active immune response.
Each of the chordoma cell lines tested exhibited variable expression of PD-L1 and PD-L2. The U-CH1 and U-CH2 cell lines had lower basal expression of both PD-L1 and PD-L2 as compared to JHC7. Similar to previous studies, we found that expression of PD-L1 depended on culture medium [25] . The JHC7 cell line had the highest baseline expression of PD-L1 when cultured in stem cell media. When the cell line was switched to FBS containing media, the baseline and inducible expression of PD-L1 significantly decreased.
Expression of checkpoint molecules, including PD-L1 and PD-L2, is a dynamic process that is highly coordinated with changes in the tumor microenvironment. Expression of PD-L1 is responsive to the presence of Th1 related cytokines (IFN-c) while expression of PD-L2 can be upregulated by Th2 related cytokines (IL-4, IL-10, and IL-13). Furthermore, expression of PD-L1 can be induced in both cancer cells and TAMs by activation of the TLR4 or STAT pathways. Expression of PD-L2 is induced on TAMs and is regulated by activation of the IL-4R and STAT pathways (Fig. 1a) [26] . As previously reported in other tumors, we found that local cytokines modulated the surface expression of PD-L1. IFN-c increased the expression of PD-L1 and PD-L2 in the U-CH1, U-CH2, and JHC-7 cell lines. Interestingly, while expression of PD-L1 or PD-L2 was not up-regulated following exposure to IL-4 in the U-CH2 cell line at the protein level, RT-PCR showed significantly increased transcription of PD-L1 and PD-L2 mRNA following exposure to IL-4. These data indicate that post-transcriptional regulation of PD-L1 and PD-L2 mRNA transcripts may play an important role in modulating activity of the PD-1 pathway.
Glioblastoma, the most aggressive central nervous system tumor has been shown to exhibit high PDL1 expression on tumor cells, TAMs and microglia. Lower grade astrocytic tumors in contrast exhibit much lower PDL1 expression, implying that the more indolent the progression of a tumor the lower the PD-L1 expression is on the tumor cells [27] . Chordomas, are slowly growing tumors that remain undetected by the immune system for many years before they are sizeable enough to have a clinical impact. In this context it does not seem surprising that chordoma tumor cells do not express surface PD-L1. However, the mechanism by which slowly growing tumors escape immune surveillance is not yet known. Myeloid infiltration in the tumor microenvironment and the expression of immune checkpoints such as PD-L1 and PD-1 early on in the disease may be a mechanism by which recruited myeloid cells shut down a T-cell reaction against cancer cells.
Immunohistochemistry primarily localized PD-L1 expression to TAMs. Previous studies have shown that increased density of TAMs correlates with decreased survival in patients with glioblastoma, renal cell carcinoma, and breast cancer, among others [28] [29] [30] . Previous studies in cultured glioblastoma cell lines have shown that monocytes exposed to the supernatant of cultured glioma cells up-regulate expression of PD-L1, likely as a result of exposure to IL-10 [14, [30] [31] [32] . Whether the release of IL-10 is related to an autocrine or paracrine process, is a topic of ongoing investigation. In addition, future work evaluating the expression of checkpoint molecules on circulating peripheral T cells and monocytes will provide a better understanding of the systemic immune function of patients with chordomas and provide further insight into the immunologic profile of these tumors.
Conclusion
The interaction between chordomas and the host immune system is poorly understood. Here, we show that humanderived chordoma cell lines demonstrate inducible expression of PD-L1 and PD-L2, and that primary chordoma tissue shows variable expression of PD-1 and PD-L1 in infiltrating immune cells. These data are the first to report the presence of PD-1-PD-L1 pathway in chordomas. Future studies are required to understand the role of PD-1 signaling in both tumor infiltrating and peripheral immune cells and the therapeutic potential of PD-1/PD-L1 blockade in chordomas.
